Amgen (AMGN) Upgraded by BofA/Merrill

Amgen (AMGN) was Upgraded by BofA/Merrill to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. BofA/Merrill advised their Clients and Investors in a research report released on Feb 1, 2017.

Based on several research reports , Amgen was Downgraded by Credit Suisse to ” Neutral” on Dec 20, 2016. Amgen was Initiated by Oppenheimer to “Outperform” on Dec 13, 2016. Mizuho Initiated Amgen on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $164.

On the company’s financial health, Amgen reported $3.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $2.79. The company had revenue of $5811.00 million for the quarter, compared to analysts expectations of $5702.65 million. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 EPS.

No comments:

Post a Comment

Forget Rising Rates. 5 Great REITs To Buy Today

Some REITs have what it takes to outperform in this sort of environment Real estate investment trusts (REITs) have really take...